Skip to main content

Gilead Oncology Triple Negative Overview | GileadPro

Therapy areas

In triple-negative breast cancer, tumour cells lack HER2, oestrogen and progesterone receptors.1

Triple-negative breast cancer is a less common type of breast cancer.2 It is defined by its lack of human epidermal growth factor receptor 2 (HER2), oestrogen and progesterone receptors.1 Compared with other breast cancers, its tumours tend to be:4–8

  • faster growing
  • less differentiated and of a higher histologic grade
  • larger at diagnosis

Triple-negative breast cancer can be aggressive, is associated with a high rate of recurrence, and has a poor survival rate compared with other breast cancers.1,3,4

Clinical needs in triple-negative breast cancer

Dr Fiona MacLean, Senior Medical Affairs Operations Manager at Kite, a Gilead Company, discusses the main characteristics of triple-negative breast cancer in this video, including:

  • Definition and epidemiology
  • Incidence as a proportion of invasive breast cancers
  • Risk factors and median age at diagnosis
  • Prognosis compared to other subtypes
  • Metastatic triple-negative breast cancer (mTNBC)

(05:30 minutes)


  1. Fangyuan, S, et al. Oncotarget. 2017;8(42):73329-73344.
  2. Cancer Research UK. Breast cancer statistics. Available at: Accessed: January 2024.
  3. Seah DS, et al. J Natl Compr Canc Netw. 2014;12(1):71-80.
  4. American Cancer Society. Triple-negative Breast Cancer. Available at: Accessed: January 2024.
  5. Foulkes WD, et al. N Engl J Med. 2010;363(20):1938-1948.
  6. Lebert JM, et al. Curr Oncol. 2018;25(Suppl 1):S142-s50.
  7. Sharma P. Oncologist. 2016;21(9):1050-1062.
  8. Lee A, Djamgoz MBA. Cancer Treat Rev. 2018;62:110-22.

Related content

January 2024 UK-UNB-3381

Adverse events should be reported

For the UK, reporting forms and information can be found at or via the Yellow Card app (download from the Apple App Store or Google Play Store). Adverse events should also be reported to Gilead to [email protected] or +44 (0) 1223 897500.